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Abstract
Objective—Determine effect of body mass index (BMI) on response to bacterial vaginosis (BV)
treatment.
Study Design—Secondary analysis of two multicenter trials of therapy for BV and Trichomonas
vaginalis. Gravida screened for BV between 8-22 weeks and randomized between 16-23 weeks to
metronidazole or placebo. Of 1,497 gravida with asymptomatic BV and preconceptional BMI, 738
were randomized to metronidazole; BMI divided into categories: <25, 25-29.9, and ≥ 30. Rates of
BV persistence at follow-up compared using Mantel-Haenszel Chi square. Multiple logistic
regression used to evaluate effect of BMI on BV persistence at follow-up, adjusting for potential
confounders.
Results—No association identified between BMI and BV rate at follow-up (p=0.21). BMI was
associated with maternal age, smoking, marital status, and black race. Compared to women with BMI
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of <25, adjusted OR of BV at follow-up were: BMI 25-29.9: OR=0.66, 95% CI 0.43-1.02; BMI ≥
30: OR=0.83, 95% CI 0.54-1.26.
Conclusion—Persistence of BV after treatment was not related to BMI.
Keywords
body mass index; bacterial vaginosis; pregnancy; treatment
Introduction
Excessive weight has become one of the major health problems in the United States. The most
commonly used method to define obesity is the body mass index (BMI), defined as weight in
kilograms divided by height in meters, squared (kg/m2). Data from the National Health and
Nutrition Examination Survey (NHANES) 1999 which included males and non-pregnant
females indicated that 61% of adults in the United States are either overweight (BMI=25 to
29) or obese (BMI of 30 or more).1
Obese individuals have a higher percentage of fat and lower percentage of lean tissue and water
that can affect drug distribution in the tissues.2 Increased cardiac output and total blood volume
are demonstrated in the obese. Blood flow per gram of fat in nonpregnant obese patients is less
than in the non obese.2 However, the blood flow per gram of fat in pregnancy is unknown.
Obese women may have an increased volume of distribution compared to their lean
counterparts, and these changes may be particularly important with regard to drug therapy
during pregnancy.
Bacterial vaginosis (BV) is common and affects approximately 800,000 pregnant women per
year in the United States with persistence of BV after therapy reported in 22.2% of women.3
Koumans and co-investigators4 report that women delivered prematurely are more likely to
have an upper genital tract infection, and organisms associated with identified infections are
typically those found in women with BV. Bacterial vaginosis has been reported to be associated
with an increased risk of preterm delivery and delivery of low birth-weight infants, especially
in high-risk women.5-10 Our objective was to determine the effect of body mass index (BMI)
on the response to treatment among pregnant women with a confirmed diagnosis of bacterial
vaginosis.
Methods
This is a secondary analysis of data originally collected as part of two multicenter clinical trials
of therapy for BV and Trichomonas vaginalis.3 All patients with asymptomatic BV at
randomization who had follow-up results and data on preconceptional BMI were included
(N=1497). Women with symptomatic vaginitis or those with current or planned antibiotic
therapy (Chlamydia trachomatis, syphilis, gonorrhea) were excluded prior to randomization.
Women were also ineligible for randomization if antibiotics were administered in the past 2
weeks or antibiotic therapy was planned for any time prior to the onset of labor.3 BMI was
calculated using the reported height and pre-pregnant weight (weight in kilograms/height in
meters2). Pregnant women were screened for BV between 8 and 22 weeks gestation and were
randomized between 16 and 23 weeks to metronidazole (2 gm orally, repeated in 48 hours) or
identical appearing placebo. Follow-up visits were scheduled between 24.0 and 29.6 weeks
gestation and were performed at least two weeks after randomization. BV was diagnosed using
Nugent's criteria.11 Reliability of diagnosing bacterial vaginosis is improved by a standardized
method of Gram stain interpretation11 and a vaginal pH >4.4 as described in the primary
publication.3
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BMI was first evaluated as a continuous variable then categorized narrowly to assess a dose-
response relationship. We used previously defined categories for BMI. The categories were
then collapsed into three categories to increase sample sizes within strata: < 25 (normal/
underweight, n=712), 25-29.9 (overweight, n=377), and ≥ 30 (obese, n=408). The relationship
between these BMI categories and other variables including T. vaginalis at randomization,
smoking, alcohol, number of lifetime sexual partners, number of recent sexual encounters,
ethnicity, marital status, source of medical care payment, parity, and age was assessed in
univariate analyses. Categorical variables were compared using the Chi-square test and
continuous variables were compared using the Kruskal-Wallis test. Rates of BV persistence at
follow up were compared using Mantel-Haenszel Chi-square test for trend. Variables found to
be significant in univariate analysis were included in a multivariate logistic regression to
evaluate the effect of BMI on persistence of BV at follow-up controlling for these potential
confounders
Results
Of the 2,570 patients randomized in the trials, there were 1733 women with asymptomatic BV
at randomization. A total of 1,497 had both preconceptional BMI data and follow up results
available. Seven hundred thirty eight were randomized to treatment and 759 received placebo.
BMI ranged from 15-71 (median 25.5 kg/m2). Of the 738 women in the treatment arm, 339
(46%) women had a BMI<25, 200 (27%) women had a BMI of 25-29.9, and 199 (27%) had a
BMI ≥30. Among the 738 women receiving therapy, there was no association between BMI
and rate of BV at follow-up: <25: 27%; 25-29.9: 21%; ≥30: 24%, p=0.21 (Figure 1). BMI was
associated with maternal age, smoking, marital status and black race (Table 1); therefore
logistic regression was used to adjust for the effect of these variables. Compared to women
with a BMI of <25, the adjusted odds ratios of BV at follow-up for the heavier categories were:
BMI 25-29.9: OR=0.66, 95% CI 0.43, 1.02, and BMI≥30: OR=0.83, 95% CI 0.54, 1.26 (Table
2). Furthermore, odds of BV at follow-up were not significantly different when BMI was
included in the multivariate model as either a continuous variable or as a quadratic variable.
No significance differences were identified in the population among this cohort and women
who were excluded.
Discussion
Although the literature is replete with articles addressing antibiotic therapy during pregnancy,
there is a paucity of information regarding the pharmacokinetics of various antibiotics during
gestation, especially in obese pregnant women. There does, however, appear to be a decrease
in the serum levels of most antibiotics during pregnancy.12,13 Pregnant women have an
increased blood volume and increase in body fat. Serum albumin levels are decreased which
affects the distribution of drugs into maternal tissues. Additional physiologic alterations in
pregnancy that may affect drug distribution and bioavailability are slowed gut motility and the
transplacental transfer of drugs.
Metronidazole is an antiprotozoal and antibacterial agent with the major route of elimination
the urine (60-80%), the main site of metabolism the liver, and volume of distribution that of
total body water.14 A linear relationship exists between metronidazole doses of 200 to 2000
mg and plasma concentration, and average effective concentrations of the drug are 8mcg/mL
for most susceptible protozoa and bacteria.14 Bioavailability of metronidazole in the non-
pregnant individual approaches 100% with an elimination half-life of about 8 hours.14 Dosage
recommendations for children with amebiasis are weight-based. For anaerobic infections in
adults, intravenous metronidazole is administered on a weight basis.
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With the increasing prevalence of overweight and obese adults in the U.S., more overweight
and obese women are now encountered in obstetric practices across the country. Moreover,
the effects of obesity on drug distribution during pregnancy are largely unknown. Our
hypothesis is that women with an increased BMI would have more treatment failures due to a
larger volume of distribution, decreased plasma levels of metronidazole, and an increased renal
clearance. BMI in this study was evaluated as a continuous variable prior to being categorized
narrowly due to sample size. Originally we looked at five categories of BMI using a standard
definition. Since the N were small in the two extreme groups (underweight and morbidly
obese), we combined them with the next severe group. We found that among the 738 women
receiving treatment, there was no association between BMI and rate of BV at follow-up. When
logistic regression analysis was utilized to adjust for the effect of the potential confounders
(maternal age, smoking, marital status and black race), the adjusted odds ratio of BV at follow-
up for the heavier women was not increased as compared to their lean counterparts.
Of note, since the time of the original study, updated Sexually Transmitted Diseases Treatment
Guidelines published by the Centers for Disease Control and Prevention (2006)15 caution that
metronidazole 2-g single-dose therapy has the lowest efficacy for BV and is no longer a
recommended treatment regimen. In conclusion, persistence of BV after treatment in pregnant
women is not related to BMI after controlling for potential confounding factors, and failure of
therapy was not more common among obese women. Further studies are needed to see if our
data can be extrapolated to a less socioeconomically-deprived population.
Acknowledgments
Supported by grants from the National Institute of Child Health and Human Development (HD21410, HD21414,
HD27860, HD27861, HD27869, HD27883, HD27889, HD27905, HD27915, HD27917, HD34116, HD34122,
HD34136, HD34208, HD34210, HD19897 and HD36801) and the National Institute of Allergy and Infectious
Diseases (AI 38514).
In addition to the authors, other members of the National Institute of Child Health and Human Development Maternal-
Fetal Medicine Units Network are as follows:
University of Alabama at Birmingham — R.L. Copper, A. Northen, and W.W. Andrews
University of Chicago — P. Jones and M.D. Lindheimer
University of Cincinnati — N. Elder and T.A. Siddiqi
The George Washington University Biostatistics Center — E.Thom, S. Leindecker, and M.L. Fischer
University of Pittsburgh — R. Phillip Heine, Steven N. Caritis, T. Kamon, and J Roberts.
University of Miami — S. Beydoun, C. Alfonso, and F. Doyle
National Institute of Child Health and Human Development — D. McNellis, C. Catz and S.J. Yaffe
Ohio State University — Wayne Trout, F. Johnson, and M.B. Landon
University of Oklahoma — G. Thurnau and A. Meier
Medical University of South Carolina — B.A. Collins, F. LeBoeuf, and R.B. Newman
University of Tennessee — B.M. Mercer and R. Ramsey
University of Texas at San Antonio — M. Berkus and S. Nicholson
University of Texas Southwestern Medical Center — M.L. Sherman. And S. Bloom,
Thomas Jefferson University — M. DiVito and J. Tolosa
Mastrobattista et al. Page 5













University of Utah — D. Dudley and L. Reynolds
Wake Forest University — P. Meis, E. Mueller-Heubach, and M. Swain
Wayne State University — S.F. Bottoms (deceased) and G.S. Norman.
Consultants: Sharon L. Hillier, Ph.D., University of Pittsburgh
Robert P. Nugent, Ph.D., M.P.H., National Institute of Child Health and Human Development
References
1. CDC National Center for Chronic Disease Prevention and Health Promotion: Nutrition and Physical
Activity. Defining overweight and obesity. Available at:
http://www.cdc.gov/nccdphp/dnps/obesity/defining.htm
2. Cheymol G. Drug pharmacokinetics in the obese. Fundam Clin Pharmacol 1988;2(3):239–256.
[PubMed: 3042569]
3. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant
women with asymptomatic bacterial vaginosis. N Engl J Med 2000;342:534–540. [PubMed:
10684911]
4. Koumans EL, Markowitz LE, Hogan V, CDC BV Working Group. Indications for therapy and
treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: A synthesis
of data. Clin Infect Dis 2002;35(Suppl 2):S152–172. [PubMed: 12353202]
5. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm
delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med
1995;333:1732–1736. [PubMed: 7491136]
6. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm
delivery of a low-birth-weight infant. N Engl J Med 1995;333:1737–1742. [PubMed: 7491137]
7. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslei P. Bacterial vaginosis as a risk
factor for preterm delivery: A meta-analysis. Am J Obstet Gynecol 2003;189:139–147. [PubMed:
12861153]
8. Carey JC, Klebanoff MA, National Institute of Child Health and Human Development Maternal-Fetal
Medicine Units Network. What have we learned about vaginal infections and preterm birth? Semin
Perinatol 2003;27:212–216. [PubMed: 12889588]
9. Kekki M, Kurki T, Kotomaki T, Sintonen H, Paavonen J. Cost-effectiveness of screening and treatment
for bacterial vaginosis in early pregnancy among women at low risk for preterm birth. Acta Obstet
Gynecol Scand 2004;83:27–36. [PubMed: 14678083]
10. Tebes CC, Lynch C, Sinnott J. The effect of treating bacterial vaginosis on preterm labor. Infect Dis
Obstet Gynecol 2003;11:123–129. [PubMed: 14627219]
11. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a
standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297–301. [PubMed:
1706728]
12. Chow AW, Jewesson PJ. Pharmacokinetics and safety of antimicrobial agents during pregnancy. Rev
Infect Dis 1985;7:287–313. [PubMed: 3895351]
13. Niebyl JR. Antibiotics and other anti-infective agents in pregnancy and lactation. Am J Perinatol
2003;20:405–414. [PubMed: 14703588]
14. Tracy, JW.; Webster, LT, Jr. Drugs used in the chemotherapy of protozoal infections. In: Hardman,
JG.; Limbird, LE.; Gilman, AG., editors. Goodman & Gilman's The Pharmacologic Basis of
Therapeutics. 10th. New York: McGraw-Hill Medical Publishing Division; 2001. p. 1097-1120.
15. Centers for Disease Control and Prevention. Workowski KA, Berman SM. Sexaully transmitted
diseases treatment guidelines 2006. MMWR Recomm Rep 2006;55(No RR11):1–94. [PubMed:
16888612]
Mastrobattista et al. Page 6













Figure 1. Persistence of BV at follow up by BMI category
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Table 1
Summary of baseline variables by BMI category
< 25 (n=339) 25-29.9 (n=200) ≥ 30 (n=199) p-value
TV + at randomization 42 (12%) 16 (8%) 23 (12%) 0.27
Black race 240 (71%) 145 (73%) 167 (84%) 0.002
Married 96 (28%) 76 (38%) 55 (28%) 0.03
Maternal age 22.5 ± 5.4 24.1 ±5.7 24.2 ± 5.4 <0.0001
Source of medical care payment 0.30
 Government 288 (85%) 165 (83%) 179 (90%)
 Private insurance 19 (6%) 12 (6%) 7 (4%)
 None/self-paid 32 (9%) 23 (12%) 13 (7%)
Smoked during pregnancy 74 (22%) 26 (13%) 30 (15%) 0.02
Alcohol during pregnancy 29 (9%) 15 (8%) 13 (7%) 0.69
Lifetime sexual partners 0.21
 1-2 85 (25%) 47 (24%) 40 (20%)
 3-5 155 (46%) 78 (39%) 85 (43%)
 6 or more 99 (29%) 74 (37%) 73 (37%)
Number of times/week patient
had intercourse
0.85
 Up to 1 188 (55%) 117 (59%) 109 (55%)
 2-4 127 (37%) 72 (36%) 79 (40%)
 5 or more 24 (7%) 11 (6%) 11 (6%)
Parity 0.13
 0 163 (48%) 76 (38%) 85 (43%)
 1 98 (29%) 61 (31%) 56 (28%)
 2 or more 78 (23%) 63 (32%) 58 (29%)
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Table 2
Adjusted Odds Ratios* for BV positive at Follow-up by BMI category
OR 95% Confidence Interval
Obese (BMI ≥ 30) 0.83 0.54 – 1.26
Overweight (BMI 25-29.9) 0.66 0.43 – 1.02
Normal/underweight (BMI < 25) reference
*
Adjusted for maternal age, smoking, marital status and black race.
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